Glomerulonefrite

Referências

Principais artigos

Couser WG. Glomerulonephritis. Lancet. 1999 May 1;353(9163):1509-15. Resumo

Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 Feb;95(2):268-80.Texto completo  Resumo

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2012;2(suppl 2):139-274.Texto completo

Arimura Y, Muso E, Fujimoto S, et al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016 Jun;20(3):322-41.Texto completo  Resumo

Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015 Mar 18;(3):CD001533.Texto completo  Resumo

Artigos de referência

1. Couser WG. Glomerulonephritis. Lancet. 1999 May 1;353(9163):1509-15. Resumo

2. Hricik DE, Chung-Park M, Sedor JR. Glomerulonephritis. N Engl J Med. 1998 Sep 24;339(13):888-99. Resumo

3. Sethi S, Haas M, Markowitz GS, et al. Mayo Clinic/Renal Pathology Society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol. 2016 May;27(5):1278-87.Texto completo  Resumo

4. Khanna R. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome. Mo Med. 2011 Jan-Feb;108(1):33-6.Texto completo  Resumo

5. Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev. 2014 Jul;13(7):723-9. Resumo

6. Haas M, Meehan SM, Karrison TG, et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997 Nov;30(5):621-31. Resumo

7. United States Renal Data System. USRDS 1997 annual data report. 1997 [internet publication].Texto completo

8. Braden GL, Mulhern JG, O'Shea MH, et al. Changing incidence of glomerular diseases in adults. Am J Kidney Dis. 2000 May;35(5):878-83. Resumo

9. Briganti EM, Dowling J, Finlay M, et al. The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant. 2001 Jul;16(7):1364-7. Resumo

10. Simon P, Ramee MP, Boulahrouz R, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004 Sep;66(3):905-8.Texto completo  Resumo

11. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004 Sep;66(3):920-3.Texto completo  Resumo

12. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004 Nov;44(5):815-25. Resumo

13. Chadban SJ, Atkins RC. Glomerulonephritis. Lancet. 2005 May 21-27;365(9473):1797-806. Resumo

14. Kluth DC, Erwig LP, Rees AJ. Multiple facets of macrophages in renal injury. Kidney Int. 2004 Aug;66(2):542-57.Texto completo  Resumo

15. Ikezumi Y, Kanno K, Karasawa T, et al. The role of lymphocytes in the experimental progressive glomerulonephritis. Kidney Int. 2004 Sep;66(3):1036-48.Texto completo  Resumo

16. Tipping PG, Holdsworth SR. T cells in glomerulonephritis. Springer Semin Immunopathol. 2003 May;24(4):377-93. Resumo

17. Tanaka T, Kuroiwa T, Ikeuchi H, et al. Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. J Am Soc Nephrol. 2002 Oct;13(10):2488-96.Texto completo  Resumo

18. Johnson RJ. The glomerular response to injury: progression or resolution? Kidney Int. 1994 Jun;45(6):1769-82.Texto completo  Resumo

19. Brady HR. Leukocyte adhesion molecules and kidney diseases. Kidney Int. 1994 May;45(5):1285-300.Texto completo  Resumo

20. Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol. 2005 May;16(5):1195-204.Texto completo  Resumo

21. Couser WG. Mechanisms of glomerular injury in immune complex glomerulonephritis. Kidney Int. 1985 Sep;28(3):569-83.Texto completo  Resumo

22. Tejani A, Ingulli E. Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts. Nephron. 1990;55(1):1-5. Resumo

23. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002 Sep 5;347(10):738-48. Resumo

24. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int. 1990 Feb;37(2):663-76.Texto completo  Resumo

25. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993 Feb 18;328(7):465-70.Texto completo  Resumo

26. Neugarten J, Baldwin DS. Glomerulonephritis in bacterial endocarditis. Am J Med. 1984 Aug;77(2):297-304. Resumo

27. Klotman PE. HIV-associated nephropathy. Kidney Int. 1999 Sep;56(3):1161-76.Texto completo  Resumo

28. Weiner NJ, Goodman JW, Kimmel PL. The HIV-associated renal diseases: Current insight into pathogenesis and treatment. Kidney Int. 2003 May;63(5):1618-31.Texto completo  Resumo

29. Seligman VA, Lum RF, Olson JL, et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med. 2002 Jun 15;112(9):726-9. Resumo

30. Balow JE. Renal vasculitis. Kidney Int. 1985 Jun;27(6):954-64.Texto completo  Resumo

31. Eagen JW, Lewis EJ. Glomerulopathies of neoplasia. Kidney Int. 1977;11:297-306.

32. Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999 Jul;56(1):355-77.Texto completo  Resumo

33. Moulin B, Ronco PM, Mougenot B, et al. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int. 1992 Jul;42(1):127-35.Texto completo  Resumo

34. Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 Feb;95(2):268-80.Texto completo  Resumo

35. Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: A questionnaire-based survey. Am J Kidney Dis. 2000 Mar;35(3):448-57. Resumo

36. European Medicines Agency. PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system. April 2014 [internet publication].Texto completo

37. Ramachandran R, Hn HK, Kumar V, et al. Tacrolimus combined with corticosteroids versus modified ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology (Carlton). 2016 Feb;21(2):139-46. Resumo

38. Beer A, Mayer G, Kronbichler A. Treatment strategies of adult primary focal segmental glomerulosclerosis: a systematic review focusing on the last two decades. Biomed Res Int. 2016;2016:4192578.Texto completo  Resumo

39. Ren S, Wang Y, Xian L, et al. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: a network meta-analysis. PLoS One. 2017 Sep 12;12(9):e0184398.Texto completo  Resumo

40. Walters G, Willis NS, Craig JC. Interventions for renal vasculitis in adults. Cochrane Database Syst Rev. 2015 Sep 24;(9):CD003232.Texto completo  Resumo

41. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2012;2(suppl 2):139-274.Texto completo

42. Arimura Y, Muso E, Fujimoto S, et al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016 Jun;20(3):322-41.Texto completo  Resumo

43. Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015 Dec 3;373(23):2225-36.Texto completo  Resumo

44. Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015 Mar 18;(3):CD001533.Texto completo  Resumo

45. Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015 Mar;45(3):346-68. Resumo

46. Bolton WK. Goodpasture's syndrome. Kidney Int. 1996 Nov;50(5):1753-66.Texto completo  Resumo

47. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003 Mar;63(3):1164-77.Texto completo  Resumo

48. Trivedi HS, Pang MM, Campbell A, et al. Slowing the progression of renal chronic renal failure: economic benefits and patients' perspectives. Am J Kidney Dis. 2002 Apr;39(4):721-9. Resumo

49. Laczika K, Knapp S, Derfler K, et al. Immunoadsorption in Goodpasture's syndrome. Am J Kidney Dis. 2000 Aug;36(2):392-5. Resumo

50. Wheeler DC. Does lipid lowering therapy slow progression of chronic chronic kidney disease? Am J Kidney Dis. 2004 Nov;44(5):917-20. Resumo

51. Donadio JV Jr, Offord KP. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis. 1989 Dec;14(6):445-51. Resumo

52. Andrassy K, Erb A, Koderisch J, et al. Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol. 1991 Apr;35(4):139-47. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal